TearSolutions is a biotechnology company focused on the discovery, development and commercialization of novel therapies for the treatment of ocular surface disease (OSD). The company is developing bioactive proprietary peptide proteoforms of lacritin, including a patented candidate called Lacripep. Lacripep and lacritin were discovered through NIH-funded research by Dr. Gordon Laurie and are intended to optimize all three layers of the tear film while restoring corneal health and homeostasis. TearSolutions holds an exclusive license to the intellectual property from the University of Virginia Licensing and Ventures Group. The company is led by President and CEO Anil Asrani and is based in Charlottesville, VA. It intends to use recent funding to accelerate its development programs for rare corneal diseases at both pre-clinical and clinical stages.

Total raised

$3M

Funding rounds

1

Latest round

Series B

Latest activity

Nov 2024